<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13162">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755507</url>
  </required_header>
  <id_info>
    <org_study_id>NUC-3/PSC</org_study_id>
    <nct_id>NCT01755507</nct_id>
  </id_info>
  <brief_title>Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis</brief_title>
  <acronym>NUC-3</acronym>
  <official_title>Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of different doses of nor UDCA vs. placebo for the treatment of
      Primary Sclerosing Cholangitis (PSC). Identification of optimal dose(s)for the treatment of
      PSC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, multi-center, placebo-controlled, comparative exploratory phase
      II-finding trial.The study will be conducted with four treatment groups in the form of a
      parallel-group comparison and will serve to compare oral treatment with either 500 mg/d,
      1000 mg/d or 1500 mg/d norursodeoxycholic acid capsules vs. Placebo capsules for the
      treatment of PSC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in serum AP levels during treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with at least 50% reduction in s-ALP</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>norUDCA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>norUDCA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>norUDCA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norUDCA</intervention_name>
    <description>Comparison of different dosages of norUDCA acid administered orally.</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent

          2. Verified diagnosis of PSC

          3. PSC patients with or without IBD

          4. Women of childbearing potential have to apply during the entire duration of the study
             a highly effective method of birth control.

        Exclusion Criteria:

          1. History or presence of other concomitant liver diseases

          2. Treatment with UDCA within 8 weeks prior to baseline visit.

          3. Child B/C liver cirrhosis

          4. Total bilirubin &gt; 3.0 mg/dl at screening or baseline.

          5. Any relevant systemic disease

          6. TSH&gt;ULN at screening

          7. any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder

          8. Any active malignant disease

          9. Known intolerance/hypersensitivity to study drug

         10. Existing or intended pregnancy of brest feeding

         11. Simultaneous participation in another clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Trauner, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Uni Wien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael P Manns, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Hochschule Hannover</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Proels, PhD</last_name>
    <phone>+49-7611514</phone>
    <phone_ext>199</phone_ext>
    <email>proels@drfalkpharma.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prof. M. Trauner</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof. Michael Manns</name>
      <address>
        <city>Hannover</city>
        <zip>30623</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kirsten Boberg</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 25, 2013</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
